COMP <GO>
IESC vs TMO // EV/EBITDA & P/E VALUATION
IES Holdings Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: IESC 5
— TMO 7
▲ EV/EBITDA & P/E VALUATION LEADER: IESC
LAST: $223.79 (-0.77%) • MKT CAP: $9.11B
valuation
17.6x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IESC VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IESC | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 34.70% | 9.30% | +25.40 | IESC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.6x | 30.4x | -12.80 | IESC | /valuation <GO> |
| Free Cash Flow Yield | 1.47% | 2.40% | -0.93 | TMO | /fcf-yield <GO> |
| Operating Margin | 11.40% | 17.40% | -6.00 | TMO | /operating-margins <GO> |
| Net Profit Margin | 9.10% | 15.10% | -6.00 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 16.90% | 3.90% | +13.00 | IESC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.79 | 4.50 | +7.29 | IESC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.9 | 62.9 | -29.00 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.94 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 36.3x | -11.30 | IESC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.11B | $262.22B | -$253.11B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IESC REV | TMO REV | IESC GROSS % | TMO GROSS % | IESC FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.37B | $44.56B | 25.5% | — | $134.4M | $6.29B |
| FY 2024 | $2.88B | $42.88B | 24.2% | — | $104.6M | $7.27B |
| FY 2023 | $2.38B | $42.86B | — | — | $46.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IESC // BETA 0.94
TMO // BETA 0.94